// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Evaluation of a LAMP assay for detection of Prothrombin Allele and Factor V Leiden

K. Hickey - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Evaluation of Automated Mixing Studies and Calculation of Index of Circulating Anticoagulant in Samples with Lupus Anticoagulant or Factor VIII Inhibitors

S. Kamali - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Hemophilia

rivaroxaban

Evaluation of edoxaban plasma concentration data from clinical practice.

V. Speed - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Edoxaban

Evaluation of the effect of freezing and thawing of citrated plasma on coagulation assays

K. Mayger - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Fibrinogen (IV)

Evidence for mitochondrial dysfunction in blood-derived endothelial colony forming cells isolated from patients with antiphospholipid syndrome

L. Kabir - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Antiphospholipid syndrome

N/A

Experience of Therapeutic Drug Monitoring in Patients Prescribed Direct Oral Anticoagulants (DOACs) of Low Body Weight ( < 55kg) at Guy’s & St Thomas’ NHS Foundation Trust

J. Bartoli- Abdou - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Exploring hidden bleeding phenotypes by screening FXIII and Fibrinogen genes

S. Singh - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

Fibrinogen (IV)

Exploring Platelet Proteins Altered in Severe COVID-19 Using Gene Ontology (GO) Pathways

L. Goudswaard - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Extreme Long-term Stability of Aspirin Tablets and Their Ability to Inhibit Platelet Aggregation

I. Sabnis - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Aspirin

Factor XI and Plasma Kallikrein apple domain structures reveal alternate kininogen bound complexes

J. EMSLEY - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

folitixorin calcium

Factor XII heavy chain structure

J. EMSLEY - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Factor XIII levels correlate with fibrinogen concentrations in patients with venous malformations and chronic disseminated intravascular coagulopathy

N. Fordham - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous malformations

Fibrinogen (IV)

Factors influencing time from initial presentation to start of plasma exchange in patients with acute thrombotic thrombocytopenic purpura in the United Kingdom

T. Bull - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Thrombotic thrombocytopenic purpura

N/A

Fibrin Film Formation is Enhanced by Red Blood Cells and Reduces Platelet Spreading

G. Alkarithi - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Interleukin

Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin: Analysis of Antithrombin Levels and Thrombin Generation from a Phase 3 Study in People with Hemophilia A or B With Inhibitors

S. Rangarajan - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

Evithrom

Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin: Analysis of Antithrombin Levels and Thrombin Generation from a Phase 3 Study in People with Hemophilia A or B Without inhibitors

S. Pipe - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

Evithrom

FIX binding to collagen IV generates thrombin via the extrinsic tenase

G. Morrow - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Evithrom

Frequency of reported thrombotic adverse events and clinical outcomes associated with three COVID-19 vaccines

M. Tobaiqy - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

FRONTIER1: A Phase 1/2 Dose Escalation Study of a Novel Factor VIIIa Mimetic Bispecific Antibody, Mim8, for Evaluation of Safety, Pharmacokinetics, and Efficacy

P. Chowdary - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Fully automated platelet Differential Interference Contrast image analysis via deep learning.

C. Kempster - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Fibrinogen (IV)

Copyright © 2026. QuantiNova All rights reserved